and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial NEW ...
Shares of ARVN stock opened at $17.67 on Wednesday. The stock has a market cap of $1.21 billion, a P/E ratio of -3.78 and a beta of 1.88. The stock has a fifty day moving average price of $19.04 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback